R06.6 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM R06.6 became effective on October 1, 2019. This is the American ICD-10-CM version of R06.6 - other international versions of ICD-10 R06.6 may differ.
Low income. Z59.6 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM Z59.6 became effective on October 1, 2019.
Hiccough. The 2019 edition of ICD-10-CM R06.6 became effective on October 1, 2018. This is the American ICD-10-CM version of R06.6 - other international versions of ICD-10 R06.6 may differ.
However, low levels if IL-6 do not preclude disease progression and future development of severe inflammatory response. • A false negative result may occur if the test reports lower values than actual levels of IL-6 that are in the sample.
Elecsys IL-6 immunoassay is an in-vitro diagnostic test for the quantitative determination of IL-6 (interleukin-6) in human serum and plasma. 1,2 This assay is used to assist in identifying severe inflammatory response in patients with confirmed COVID-19 illness to aid in determining the risk of intubation with mechanical ventilation, in conjunction with clinical findings and the results of other laboratory testing.
8 IL-6 is produced locally at the site of infectious or injured lesions and is delivered to the whole body via the blood stream, promptly activating the host defense system to perform diverse functions. 6 This essential cytokine stimulates acute phase reactions, immune responses, hematopoiesis and various internal organs to prepare for host defense. 6 IL-6 is an important mediator of fever and the acute phase response that enhances the innate immune system to protect against tissue damage. 7